Pulsenmore Ltd.

The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home. This registration marks the Company’s second product authorized in Europe and its first expansion beyond prenatal care into the broader women’s health market. The post Pulsenmore Expands Its Fertility Business into the UK appeared first on PULSENMORE | Home Ultrasound.

The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home. This registration marks the Company’s second product authorized in Europe and its first expansion beyond prenatal care into the broader women’s health market. The post Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring appeared first on PULSENMORE | Home Ultrasound.

Ramat Gan, Israel, July 15, 2026 – Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced growing clinical evidence supporting the expansion of its home ultrasound platform beyond individual ultrasound measurements toward more advanced prenatal assessments The post Pulsenmore Expands Home Ultrasound Clinical Utility, Backed by New Clinical Evidence appeared first on PULSENMORE | Home Ultrasound.

In this pilot study, patient-operated remote ultrasonography was feasible for completing BPPs in high-risk pregnancies. This new technology may improve access to critical antenatal surveillance services, particularly for patients facing access barriers such as lacking transportation or living in maternity care deserts. The post Patient-operated remote ultrasonography for completing biophysical profiles for antenatal surveillance in high-risk pregnancies appeared first on PULSENMORE | Home Ultrasound.

RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in connected home ultrasound technology, today announced that it has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (IIA) and the Ministry of Health. Pulsenmore will receive funding from the IIA as part of a project. The post Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead a $1 Million AI Development Project appeared first on PULSENMORE | Home Ultrasound.

RAMAT GAN, Israel, June 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a strategic partnership with Ouma Health, a leading provider of virtual maternity care solutions in the United States. The post Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States. appeared first on PULSENMORE | Home Ultrasound.

Abstract Objective To evaluate the feasibility and accuracy of remote, clinician-guided biophysical profile (BPP) assessment using a handheld ultrasound device operated by lay users. Methods This prospective, non-randomized, quasi-blinded study compared clinician-guided ultrasound-based BPP scans performed remotely by lay users using the Pulsenmore ES device with concomitant standard in-clinic ultrasound examinations performed by healthcare professionals, with both assessments conducted consecutively and immediately one after the other. Agreement between modalities was assessed for individual BPP components and overall BPP scores. Results A total of 30 pregnant women were enrolled at a mean gestational age of 33.0?±?2.6?weeks. The mean maternal age was 31.4?±?4.5?years, and mean body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) was 27.4?±?5.2. Overall agreement between remote and in-clinic BPP scores was 90%. Agreement was 100% for cardiac activity, fetal movements, fetal presentation, placental location, and subjective amniotic fluid volume assessment. Agreement for fetal tone and breathing movements was 96.7 and 93.3%, respectively. Sensitivity and specificity of remote BPP assessment for detecting abnormal overall BPP findings, using the standard in-clinical ultrasound examination as the reference standard, were 92.6 and 66.7%. The mean difference in total BPP score was 0.07?±?0.64 points. Mean fetal heart rate and maximal vertical pocket measurements were comparable between modalities. Remote examinations required more time than in-clinic scans (8.0?±?3.9 vs. 4.6?±?3.3?min) but remained within recommended limits. Conclusion Clinician-guided remote BPP assessment using a handheld ultrasound device operated by lay users demonstrates high agreement with standard in-clinic ultrasound under supervised conditions and may represent a reliable alternative for prenatal surveillance in selected populations. The post Biophysical profile by self-operated clinician-guided ultrasound versus standard ultrasound: An observational study appeared first on PULSENMORE | Home Ultrasound.